Lantus

Insulin glargine, the active ingredient in Lantus, is a long‑acting insulin analog presented as a 100 U/mL injectable solution for subcutaneous use. It provides basal insulin coverage to help control blood glucose levels in adults and children with type 1 and type 2 diabetes mellitus, supporting steady glycemic management throughout the day and night.

GNH USA supplies Lantus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution governed by EU‑based manufacturing standards and quality assurance protocols, and ensures timely delivery.

Lantus (insulin glargine) is a long‑acting insulin analog used to provide basal insulin support in the management of diabetes. - Type 1 diabetes mellitus: maintains basal glucose control throughout day and night, reducing hyperglycemia episodes. - Type 2 diabetes mellitus: complements oral antidiabetic agents or other insulins to achieve target glycemic levels. - Pediatric diabetes: offers stable basal insulin for children with type 1 diabetes, facilitating growth‑appropriate glucose management.

The most frequently reported adverse reactions with insulin glargine relate to its pharmacologic action and injection site. Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dose is excessive. - Injection site reactions: redness, swelling, or itching at the administration site. - Weight gain: gradual increase in body weight associated with improved glycemic control. - Edema: mild fluid retention, often transient. Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare systemic allergic response that may include hives, airway swelling, or shock. - Insulin antibody formation: immune response that can alter insulin efficacy. - Lipohypertrophy necrosis: severe localized tissue damage at injection sites.

When using insulin glargine, several precautions should be observed to ensure safe and effective therapy. - Blood glucose monitoring: check levels regularly to adjust dose as needed. - Dose adjustments with steroids: increase dose when patients start systemic corticosteroids. - Renal or hepatic impairment: use caution and consider lower starting doses. - Hypoglycemia unawareness: avoid in patients who cannot perceive low glucose symptoms. - Pregnancy and lactation: category B; discuss risks and benefits with healthcare provider. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin glargine may interact with other medicines, affecting glucose control or insulin action. Major Interactions (Avoid): - Concomitant use with other insulins or rapid‑acting insulin analogs: risk of severe hypoglycemia. - Sulfonylureas and meglitinides: additive glucose‑lowering effect, may cause hypoglycemia. - Beta‑blockers: can mask hypoglycemia symptoms, complicating detection. Moderate Interactions (Monitor Closely): - Systemic corticosteroids: increase insulin resistance, may require higher insulin dose. - Thiazide diuretics: may raise blood glucose, necessitating dose adjustment. - ACE inhibitors and ARBs: can affect potassium balance and renal function, influencing insulin requirements. - Antidepressants (e.g., SSRIs): may alter appetite and glucose metabolism, requiring monitoring.